Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Key Sessions

Dr. Andrew Bradbury

Chairman’s Opening Remarks

Los Alamos National Laboratories

Dr. Dennis Burton

Progress toward a Neutralizing Antibody-based HIV Vaccine

The Scripps Research Institute

Dr. Paul Richardson

Monoclonal Antibody Therapy in Multiple Myeloma, with a Focus on Daratumumab and Transforming Outcome

Dana-Farber Cancer Institute

Dr. Olivera Finn

Prophylactic Cancer Vaccines as a Source of Therapeutic Antibodies

University of Pittsburgh School of Medic

7:15 am 8:15 am (60 mins)

Main agenda

Registration and Coffee

8:15 am 8:25 am (10 mins)

Main agenda

Chairman’s Opening Remarks

  • Chairman Dr. Andrew Bradbury - Research Scientist and Group Leader, Los Alamos National Laboratories

8:25 am 9:10 am (45 mins)

Main agenda

Progress toward a Neutralizing Antibody-based HIV Vaccine

Rapid progress in (1) the isolation and characterization of broadly neutralizing antibodies (bnAbs) to HIV (2) the determination of the structure of the target of such antibodies, the HIV Envelope trimer, and (3) understanding of crucial features in the development of neutralization breadth in natural infection have stimulated HIV vaccine design efforts. Many immunogens and immunization strategies are being investigated in a diversity of animal models and new modalities for the analysis of responses are being evaluated. 

  • Speaker Dr. Dennis Burton - Professor and Chairman, The Scripps Research Institute

9:10 am 9:15 am (5 mins)

Main agenda

Keynote Questions

  • Dr. Dennis Burton - Professor and Chairman, The Scripps Research Institute

9:15 am 10 am (45 mins)

Main agenda

Monoclonal Antibody Therapy in Multiple Myeloma, with a Focus on Daratumumab and Transforming Outcome

Monoclonal antibody (MoAb) therapy has provided a paradigm shift in the management of multiple myeloma (MM) over the last several years, with the breakthrough status afforded to the CD 38 targeting MoAb daratumumab (Dara) and the regulatory approval of both daratumumab and the SLAM F7 targeting MoAb elotuzumab (Elo) for the treatment of relapsed and relapsed, refractory MM in 2015. 

Current studies have demonstrated unprecedented clinical benefit in early relapse in combination with both lenalidomide and bortezomib when each are added to Dara. The further development of both Dara and Elo in MM is ongoing, with other MoAbs, including Isatuximab (which also targets CD38), and the incorporation of checkpoint inhibitors underway.

  • Speaker Dr. Paul Richardson - Clinical Director, Dana-Farber Cancer Institute

10 am 10:05 am (5 mins)

Main agenda

Keynote Questions

  • Dr. Paul Richardson - Clinical Director, Dana-Farber Cancer Institute

10:05 am 10:35 am (30 mins)

Main agenda

Networking Refreshment Break

10:35 am 11:20 am (45 mins)

Main agenda

Prophylactic Cancer Vaccines as a Source of Therapeutic Antibodies

Therapeutic cancer vaccines have shown low immunogenicity and marginal clinical impact. This has led to efforts to test them in healthy individuals at risk for cancer. High titers, clonal variety and high affinity antibodies are induced that can be developed as fully human reagents for antibody and CAR therapy.

  • Speaker Dr. Olivera Finn - Distinguished Professor, University of Pittsburgh School of Medic

11:20 am 11:25 am (5 mins)

Main agenda

Keynote Questions

  • Dr. Olivera Finn - Distinguished Professor, University of Pittsburgh School of Medic

11:25 am 12 pm (35 mins)

Main agenda

Antigen- and Fc-Dependent IgG Hexamer Formation: from Biology to Platform to Product

The complement system serves as an important immune defense system, protecting us from infections. By studying IgG-mediated complement activation we learned how antibodies optimally interact at the molecular level: after binding to their cognate antigen expressed on a cell-surface, IgG molecules may organize in ordered hexamers, the optimal docking and activation unit for C1.The presentation will cover structure-function aspects of hexamer formation and translation of this knowledge to a technology which selectively facilitates hexamerisation of IgG on opsonized cells. Applications in cancer and infectious disease will be discussed.

  • Speaker Janine Schuurman, Ph.D. - Vice President, Research, Genmab

12 pm 12:05 pm (5 mins)

Main agenda

Keynote Questions

12:15 pm 1:15 pm (60 mins)

Main agenda

Going Natural to Streamline and De-risk Development of Bispecific Antibodies

Numerous elegant protein engineering approaches have been described to force antibody fragments into bispecific formats. However, it appears that modified proteins can often present expression, processing and stability issues that hamper their progression towards the clinic and increase the potential for immunogenicity in humans. We have taken a different and somewhat counter-intuitive approach to generate bispecific IgGs that are structurally identical to human IgG. 

This platform, relying on the use of different antibody light chains, has now reached a high level of maturity having generated thousands of molecules. It enables ‘in format’ high throughput screening as well as scalable and generic manufacturing. The same approach is applied for the generation of surrogate molecules for use in animal models. Examples covering discovery, use in animal models of human disease, non-human primate studies and GMP production will be presented, highlighting the challenges and benefits of working with an unmodified bispecific antibody format.

Nicolas Fischer, Ph.D., Head of Research, Novimmune SA, Switzerland

  • Speaker Nicolas Fischer, Ph.D. - Head of Research , Novimmune SA

12:15 pm 1:15 pm (60 mins)

Main agenda

Precisely Controlled, Highly Diverse Gene Mutant Libraries for Synthetic Biology and Bio-therapeutic Drug Discovery

Effective synthetic libraries are critical for successful discovery and development. Twist's innovative silicon-based DNA synthesis, reaction volumes are miniaturized by a factor of 1000. By implementing rational design and expertise in synthetic DNA, Twist synthesize's each variant individually. This results in libraries with exceptional representation and diversity and screening efficiency.

  • Speaker Emily Le Proust, Ph.D. - Chief Executive Officer, Twist Bioscience

12:15 pm 1:15 pm (60 mins)

Main agenda

OmniRat, OmniMouse, Omniflic: Transgenic Animals for the Generation of Fully Human Antibodies

OmniAb®includes three transgenic animals for generation of human antibodies. OmniRat®and OmniMouse® generate antibodies with human idiotypes as effectively aswildtype animals make rat antibodies. OmniFlic® is an engineered rat with afixed light chain for the development of bi-specific antibodies. OmniAbantibodies have been generated with more than 100 therapeutic targets. Thefirst OmniAb antibody entered phase I trials in 2016.

  • Roland Buelow, Ph.D. - Vice President, Antibody Technologies , Ligand Pharmaceuticals

12:15 pm 1:15 pm (60 mins)

Main agenda

Strategic Intellectual Property Perspectives for developing Antibody, Therapeutics and Biosimilars

Intellectual property plays an important role in antibody therapeutics and biosimilars. Strategies for protecting potential antibody therapeutics are complex and take planning to develop. Equally complex are the IP considerations for developing a Biosimilar. These complexities and strategies will be discussed by Industry Experts.

  • Jeffrey Guise - Partner, Patents and Innovations, Wilson Sonsini Goodrich & Rosati
  • Jennifer Kaufman-Shaw - VP Intellectual Property & Legal Affairs, Zymeworks, Inc.
  • Diane Retallack - Senior Director Upstream Processing & IP, Pfenex, Inc.

1:15 pm 1:45 pm (30 mins)

Main agenda

A New Approach to Generating Fully Human Antibodies to GPCRs, Ion Channels, Multi-subunit Complexes and other Challenging Membrane Targets

Antibodies to membrane targets have traditionally been generated against solubilized forms or extracellular domains of the target of interest. Unfortunately, this approach is often unsuitable for complex membrane targets. We present a novel extension of De Novo engineering to screen billions of fully human antibodies for binding to membrane targets expressed in their natural environment.

  • Speaker Dr. Craig Pigott - Director of Research, Innovative Targeting Solutions, Inc.

1:15 pm 1:45 pm (30 mins)

Main agenda

F-star: Advancing Novel Bispecific Antibody Biologics Using the iQue Screener Platform

F-star develops novel bispecific antibodies (called mAb2) based on a unique modular approach. Using this cutting-edge technology, F-star is building a product pipeline focused on immuno-oncology. This talk will highlight the pivotal role the iQue Screener played in increasing the screening throughput of Fcab (antigen-binding Fc domain) candidates against several antigens.

  • Speaker Frederick Akele - Senior Research Associate, F-star Biotechnology Ltd.

1:15 pm 1:45 pm (30 mins)

Main agenda

An Integrated Approach to Managing Immunogenicity Risk and Drug Immune Modulation

Immunogenicity is a very complex issue to address in drug design and development. Integrated platforms such as Mass Spectroscopy antigen presentation assays; DC-T and T cell proliferation assays for biologic lead selection/optimization; HLA-peptide binding assays to characterize individual epitopes and undiluted whole blood cytokine storm assays, can be used to mitigate immunogenicity risk and characterize immune responses directed toward biologics.

  • Speaker Emily Knowlton, Ph.D. - Immunology Sales Specialist , ProImmune, Inc.

1:45 pm 2:15 pm (30 mins)

Main agenda

Computational Advances in Antibody Discovery: Toward Earlier Assessment, Triage and Optimization

In the field of antibody drug discovery, there is growingrealization that methods to assess, triage, and avoidliabilities in potential candidates must come early in thediscovery process. Recent advances in computationalapproaches for antibody structure prediction,identification of protein liabilities (such as aggregationpropensity), and in methods for protein engineering holdsubstantial promise in moving us closer to reaching thisgoal in an effective and efficient manner.

  • Dr. David Pearlman - Senior Principal Scientist, Schrödinger

1:45 pm 2:15 pm (30 mins)

Main agenda

Rapid Generation of Multispecific Therapeutic Antibodies Using Human Immunoglobulin (Ig) Transgenic Rats and a Robust Next Generation Sequence-based Discovery Platform


Human immunoglobulin transgenic rats (UniRat™ and OmniFlic™), next-generation sequencing and bioinformatics were applied to identify heavy chain only and common light chain antibodies (Abs) against antigens of interest.   High-throughput expression cloning and secondary Ig repertoire screening of binder Ig families enabled the selection of Abs with diverse epitope specificities, species cross-reactivity, and broad affinity ranges (70 pM to 300 nM) against T cell and tumor targets of interest.  Lead candidates were selected for favorable developability and manufacturability profiles. Variable heavy chain domains (UniDabs™) and common light chain (CL), OmniFlic™ antibodies were combined to engineer bi- and multi-specific antibodies in novel T-cell redirection platforms.  These versatile platforms, using anti-CD3’s of tune-able affinity, were shown to be highly effective in the targeted killing of both liquid and solid tumor cancer cells.  We applied these enabling technologies to develop several of bi- and multi-specific therapeutic leads for T-cell redirection and checkpoint blockade against hematological and solid tumor cancers, respectively.   The unique combination of transgenic and sequence-based discovery affords an effective approach to discover and develop well-behaved bi- and multi-specific bio-therapeutics at unprecedented speed.

  • Omid Vafa - Chief Business Officer, TeneoBio, Inc.

1:45 pm 2:15 pm (30 mins)

Main agenda

The Trianni Mouse: Best-In-Class Technology for Human Antibody Discovery

The Trianni Mouse isthe only human transgenic antibody discovery platform offering a completeheavy, kappa and lambda repertoire in a single organism. Sequences of thevariable domain exons are human while all genetic machinery includingextensively optimized promoters and enhancers are of mouse origin. Titers and classswitching are extremely robust making for highly efficient lead generation.This next-generation technology is seen as best-in-class by multiple Big Pharmaand other licensees subsequent to extensive validation and benchmarking.Additional strains in development include Plasma Ig, Autoimmune/All Epitope anda "true" Bispecific.

  • David Meininger, Ph.D. - Chief Business Officer, TRIANNI, Inc.

2:25 pm 2:30 pm (5 mins)

Main agenda

Co-Chairs Remarks

  • Chairman Dr. Dennis Burton - Professor and Chairman, The Scripps Research Institute
  • Chairman Paul Parren, Ph.D. - Senior Vice President and Scientific Director , Genmab

2:30 pm 3 pm (30 mins)

Main agenda

Rational Approach for Antibody Combo Therapies for Infectious Diseases

The combination of recombinant mAbs in the form of multi-specific antibodies or as mixtures of oligoclonal antibody products has the potential to improve their therapeutic efficacy by targeting multiple and mutating antigens to deal with pathogens heterogeneity and plasticity. Examples of anti-bacterial (Staphylococcus aureus and Klebsiella pneumoniae) and anti-viral antibodies combinations (HIV-1, Rabies and Dengue) will be presented to discuss the factors guiding the selection of appropriate therapeutic formats.

  • Speaker Dr. Davide Corti - CSO and Senior Vice President, Humabs Biomed SA

3 pm 3:30 pm (30 mins)

Main agenda

Monoclonal Antibodies-based Treatment of Ebola Virus Infection Shaped the Rapid Progression of Experimental Therapies and Vaccines

The provision of experimental treatments and vaccines has for the first time been expanded to dozens of Ebola infected men and women and in turn has been a major contributor to accelerate the clinical progression of both experimental vaccines and therapeutics. This presentation will show the contribution of emergency compassionate use of experimental clinical modalities to the overall ability to develop urgently needed counter measures. It will also review the recent advancements and future possibilities.

  • Speaker Hugues Fausther Bovendo - Scientist, University of Laval

3:30 pm 4 pm (30 mins)

Main agenda

Therapeutic Human Polyclonal Antibodies Derived from Transchromosomic Bovines for Treating Emerging Infectious Diseases

The use of passive immunotherapy to effectively prevent and treat infectious diseases has a long history and has been proposed as a treatment option for emerging diseases. SAB Biotherapeutics has developed a transchromosomic bovine platform technology and production system to rapidly produce fully human and highly potent polyclonal antibodies against a variety of emerging infectious diseases caused by viruses such as Ebola, MERS-CoV, Zika, dengue, hantavirus, and influenza virus.

  • Speaker Jin-an Jiao, Ph.D. - Chief Scientific Officer and Executive VP Product , SAB Biotherapeutics, Inc.

4 pm 4:45 pm (45 mins)

Main agenda

Networking Refreshment Break and Opening of Exhibit and Poster Hall

4:45 pm 5:15 pm (30 mins)

Main agenda

Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with IgG1 and Antigen

Biophysical characterization of the C1-IgG complex has remained elusive primarily due to the low affinity of IgG-C1q binding. Using IgG variants that dynamically form hexamers efficient in C1q binding and complement activation, we could now assess C1q binding in solution by native mass spectrometry. Molecular features of these IgG hexamers, such as glycosylation, Fab-arms and antigen-binding, are assessed for their specific role in complement activation.

  • Speaker Dr. Guanbo Wang - Associate Professor, Nanjing Normal University

5:15 pm 5:45 pm (30 mins)

Main agenda

Exploiting the Emergent Properties of Oligoclonal Antibodies to Inform New Development Opportunities for MM-151

MM-151 is an oligoclonal mixture of three fully-human IgG1 antibodies that engage non-overlapping epitopes on EGFR. Initial preclinical and clinical studies with MM-151 have identified mechanisms of action beyond those observed for monoclonal antibodies. Multiscale translational studies were performed to understand several of these emergent properties and to guide future clinical development.

  • Speaker Shawn Carey - Translational Research Scientist , Merrimack Pharmaceuticals

5:45 pm 6:15 pm (30 mins)

Main agenda

Discovery of a Bispecific Antibody Targeting EGFR and cMet Effective in EGFR Mutant Setting With cMet Pathway Activation

The DuoBody platform represents a novel and elegant post-production technology for the generation of stable bispecific antibodies, based on the controlled Fab-arm exchange process. To find the optimal combination of Fab-arms this platform was used to select a bispecific EGFR-cMet bispecific antibody (JNJ-61186372) with multiple mechanisms of action resulting in anti-tumor activity in the EGFR mutant setting, with or without cMet pathway activation.

  • Speaker Dr. Joost Neijssen - Senior Scientist, Antibody Sciences, Genmab BV

6:15 pm 7:15 pm (60 mins)

Main agenda

Networking Cocktail Reception, Exhibits and Poster Viewing

2:25 pm 2:30 pm (5 mins)

Main agenda

Co-Chairs Remarks

  • Chairwoman Jamie Scott, M.D., Ph.D. - Professor and Canada Research Chair , Simon Fraser University
  • Chairman Dr. George Georgiou - Professor, Laura Jennings Turner Chair in Engineer, The University of Texas at Austin

2:30 pm 3 pm (30 mins)

Main agenda

Antibody Discovery by Mining the Patient Serological Immune Repertoire

We have developed an experimental pipeline for the identification and relative quantitation of the monoclonal antibodies that comprise the serological repertoire in blood and secretions. Examples of several serologically identified antibodies that target unique epitopes and potently clear pathogenic cells will be presented.

  • Speaker Dr. George Georgiou - Professor, Laura Jennings Turner Chair in Engineer, The University of Texas at Austin

3 pm 3:30 pm (30 mins)

Main agenda

mAb Discovery and Vaccine Design Using High-throughput Sequencing of Paired Antibody Heavy and Light Chains

Antibody heavy and light chains are encoded by separate mRNA strands, and thus conventional NextGen sequencing fails to identify the native antibodies encoded by individual B cells. To overcome this limitation, we are applying recently-developed technologies for high-throughput sequencing of complete antibodies (i.e., paired heavy and light chains) to generate a quantitative understanding of immune responses. These advances are being used to accelerate the development of antibody therapeutics and vaccines against  HIV and other pathogens of high public health importance.

  • Speaker Dr. Brandon DeKosky - Postdoctoral Fellow, NIAID, NIH

3:30 pm 4 pm (30 mins)

Main agenda

Analyzing B-cell Receptor Repertoires from Human Studies

Understanding adaptive immunity and identifying functional antibodies from human immune responses requires accurate, single-cell characterization of lymphocyte repertoires. Atreca’s Immune Repertoire Capture (IRC™) technology reveals precise, paired immune receptor sequences and cellular, clonal counts from carefully selected B- and T-cells. Analysis of patient repertoires has produced insights into disease biology, vaccinology and potent human antibodies that target tumors, pathogens and autoantigens.

  • Speaker Dr. Daniel Emerling - Senior Vice President, Research, Atreca, Inc

4 pm 4:45 pm (45 mins)

Main agenda

Networking Refreshment Break and Opening of Exhibit and Poster Hall

4:45 pm 5:15 pm (30 mins)

Main agenda

The Antibody Response of Celiac Disease

Celiac disease is a gluten-induced disorder with autoimmune features. The patients have CD4 T cells recognizing gluten peptides that have been deaminated by the enzyme transglutaminase 2 as well as highly disease specific antibodies to the transglutaminase 2 autoantigen and to deaminated gluten peptides. Results from on the characterization of the antigen receptor repertoire of antigen specific plasma cells and T cells will be presented.

  • Speaker Dr. Ludvig Sollid - Director, Centre for Immune Regulation, Oslo University Hospital Rikshospitalet

5:15 pm 5:45 pm (30 mins)

Main agenda

Reading the Receptor Repertoire: Computational Prediction of Specificity from Primary Sequence Enables Rapid Antigen Discovery in Humans

A collection of our entire immunological history flows through our veins, but we cannot read it. T-cell and B-cell receptors, the primary mediators of adaptive immune specificity recognition, can now be read by the millions using high throughput sequencing technologies. Unfortunately, almost all receptors observed would differ across individuals, even against the same receptor target. Here we discuss a mathematical method for decoding the T-cell and B-cell receptor repertoire to enable identification of receptor specificity directly from the primary sequence. 

We review the novel algorithm, Grouping of Lymphocyte Interactions by Paratope Hotspots (GLIPH), as it is applied to rapidly identify new immunodominant shared antigen specificities in Tuberculosis patients, and to track shared immune memory to vaccines in influenza vaccine recipients. We finish by discussing how the ability to read receptor specificity from primary sequence enables detection of shared immune etiology in diseases of currently unknown causes, and has direct medical relevance in the areas of oncology, autoimmunity, allergy, infectious disease and transplant immunology.

  • Speaker Dr. Jacob Glanville - Chief Science Officer, Distributed Bio, Inc.

5:45 pm 6:15 pm (30 mins)

Main agenda

Donor-derived T-cell Receptor Repertoires to Attack Cancer

Immunotherapy can activate T cells capable of recognizing peptides from mutated proteins (neo-antigens), representing a major breakthrough in cancer treatment. However, while all cancers harbor mutations, patient T cells rarely elicit a curative response. We recently demonstrated that T cells from healthy donors may recognize neo-antigens that were neglected by T cells from melanoma patients. The implication of this work is that anti-cancer immunity can be “outsourced.”

  • Speaker Dr. Johanna Olweus - Professor, Head of Department of Immunology, Oslo University Hospital Radiumhospitale

6:15 pm 7:15 pm (60 mins)

Main agenda

Opening Night Nautical Reception with Exhibits and Poster Viewing

Join your fellow attendees in the exhibit hall for an evening of nautically-themed food, drinks and fun! Enjoy coconut lime shrimp, lobster rolls and more while taking the opportunity to learn about the latest antibody technologies and scientific innovations.